Qynapse Publications

Featured Release

All Recent Publications & Presentations at Conferences

QyScore® Clinical Utility in Alzheimer's disease & other Dementias

Publication in The Journal of Prevention of Alzheimer’s Disease – Clinical trial result:

  • Macfarlane., et al. (2025) Blarcamesine for the treatment of early Alzheimer’s disease: Results from the ANAVEX2-73-AD-004 Phase IIB/III trial

AAIC 2023 Posters:

  • Gordon E., et al. (2023) QyScore®’s fully automated quantitative image segmentation tools against expert manual gold-standards

AAIC 2022 Posters:

  • Longo dos Santos C., et al. (2022) Relationship between MTA visual scale scores and hippocampal volume measured by a medical device in patients from a multicentric memory clinic population
  • Longo dos Santos C., et al. (2022) Correlation between quantitative and qualitative assessments of white matter hyperintensities in patients from a multicentric memory clinic population
  • Schwarz A.J., et al. (2022) Prevalence and clinical associations of atrophy subtypes using clinical routine image analysis software in MCI patients from a memory clinic population
  • Gordon E., et al. (2022) Four-year cognitive decline in mild cognitive impairment patients with distinct baseline neuroanatomical atrophy profiles: A MEMENTO and QyScore® study

AAIC 2021 Poster: 

QyScore® Clinical Utility in Parkinson’s disease and other movement disorders

AD/PD 2023 Oral presentation:

  • Mambrin F., et al. (2023) Distinguishing Parkinson disease and atypical parkinsonism: Comparison of Qyscore®’s automated quantification with expert manual neuroimaging marker

ECR 2022 Oral presentation:

  • Mambrin F., et al. (2022) Comparison of the accuracy of quantitative automatic and radiological imaging markers in distinguishing Parkinson Disease and Progressive Supranuclear Palsy
QyScore® Clinical Utility in Multiple Sclerosis

ACTRIMS 2023 Poster:

Publication in Bioengineering:

  • Ziccardi., et al. (2022) Making visible the invisible: Automatically measured global and regional brain volume is associated with cognitive impairment and fatigue in multiple sclerosis

ECTRIMS 2022 Poster:

ACTRIMS 2022 Poster:

  • Tran P., et al. (2022) Automated MRI Lesion Analysis and reporting as a computer-assisted radiology tool for determination of McDonald Criteria

EAN 2021 Poster:

  • Tran P., et al. (2021) Brain Volumes Alterations in Multiple Sclerosis Patients: Comparison to QyScore® Normative Data

ACTRIMS-ECTRIMS 2020 Poster (MS Virtual 2020):

  • Tran P., et al. (2020) Brain volumes alterations in relapsing remitting multiple sclerosis patients versus healthy controls in comparison to QyScore® normative database
QyScore® Validation & Performance results

AAIC 2025 Poster:

  • Villa LM., et al. (2025) A comparison of fully-automated segmentation pipelines: Qyscore® vs Freesurfer vs FSL vs ANTs

AAIC 2024 Poster:

  • Gordon E., et al. (2024) Validation of Qyscore® white matter hyper intensity (WMH) U-NET segmentation algorithm against expert manual consensus and comparison with state-of-the-art methods

AAIC 2023 Poster:

  • Gordon E., et al. (2023) Validation of Qyscore®’s fully automated quantitative image segmentation tools against an expert manual gold-standard

Poster ESNR 2024 – Performance results:

Publication in European Radiology Journal – Validation results:

  • Cavedo E., et al. (2022) Validation of an automatic tool for the rapid measurement of brain atrophy and white matter hyperintensity: QyScore®. Eur Radiol 32, 2949–2961 (2022).
  • Cavedo E, et al. (2022) Validation of an automatic tool for the rapid measurement of brain atrophy and white matter hyperintensity in clinical routine setting: QyScore®. European Radiology. 2022;32(5):2949-2961. 

Publication in Neuroimage Clinical – Performance results:

  • Tran P., et al. (2022) Automatic segmentation of white matter hyperintensities: validation and comparison with state-of-the-art methods on both Multiple Sclerosis and elderly subjects. Neuroimage Clin. 2022;33:102940.

Poster ACTRIMS Forum 2022 – Reproducibility results: 

  • Morales-Pinzón A., et al. (2022)  Scan-rescan and field-strength reproducibility of brain volumetry and white matter lesions determined using QyScore®, a regulatory-approved automated software platform

 

QyPredict®

AAIC 2025 Posters:

  • Villa LM., et al. (2025) The Potential for MRI-based Predictive modelling for treatment prioritization and clinical trials.

AAIC 2024 Poster

AAIC 2023 Poster

  • Gordon E., et al. (2023) QyPredict prognostic model enriches selection for faster decliners in mild cognitive impairment

Symposium presentation at AD/PD 2022:

CTAD 2020 & 2021 Posters:

  • Samper-Gonzalez J., et al. (2021) QyPredict®: added value to patient selection strategies and statistical analysis in Alzheimer’s disease clinical trials
  • Movschin A., et al. (2020) Use of predictive algorithms for the selection of patients in clinical trials: an enrichment strategies comparison
Clinical Trials Biomarkers

AD/PD 2024 Poster:

  • Gordon E., et al. (2024) An automated pipeline for centiloid quantification of amyloid-B using multiple 11C-PIB-PET and 18F-PET tracers

AD/PD 2023 Poster:

  • Gordon E., et al. (2023) An automated pipeline for centiloid quantification of amyloid-B using multiple 11C-PIB-PET and 18F-PET tracers

AD/PD 2022 Poster:

  • Huet P., et al. (2022) An automated pipeline for centiloid quantification of amyloid load using multiple PET tracer

Publication in Alzheimers Dement. Journal:

  • Dubois B. et al. (2015) “Hippocampus Study Group”. Donepezil decreases annual rate of hippocampal atrophy in suspected prodromal Alzheimer’s disease. Alzheimers Dement. 2015;11(9):1041-9.
Others

Publication in Neurological Science:

  • Cecchini., et al. (2024) Long-term effects of SARS-CoV-2 infection in patients with and without chemosensory disorders at disease onset: A psychophysical and magnetic resonance imaging exploratory study
If you’re a clinical researcher, pharma or biotech, our team is standing by, ready to demonstrate the power of Qynapse. Reach out and we’ll be in touch soon.
CONTACT US